ROIVANT SCIENCES LTD. (ROIV) Operating Margin
- Operating margin · 12 months: Value -7914.75%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -7914.75% | Operating income / revenue. Period ending 2026-06-30. $-596.14M ÷ $7.53M × 100 ≈ -7914.75% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -596.14M USD | Operating Income (Loss) |
| Revenue | 7.53M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 730.91M USD | Research and Development Expense |
| Selling, general and administration | (m) | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-596.14M | $7.53M | (m) | $730.91M | (m) | -7914.75% |
| 2026-03-31 | $-515.07M | $8.26M | (m) | $681.81M | (m) | -6235.69% |
| 2025-12-31 | $-1.22B | $13.31M | (m) | $628.11M | (m) | -9130.53% |
| 2025-09-30 | $-1.15B | $20.33M | (m) | $604.32M | (m) | -5659.41% |
| 2025-06-30 | $-1.19B | $23.23M | (m) | $582.83M | (m) | -5104.73% |
| 2025-03-31 | $-1.00B | $29.05M | (m) | $550.41M | (m) | -3453.32% |
| 2024-12-31 | $-1.18B | $122.58M | (m) | $574.56M | (m) | -962.74% |
| 2024-09-30 | $4.22B | $129.13M | (m) | $541.11M | (m) | 3269.33% |
| 2024-06-30 | $4.40B | $158.30M | (m) | $509.81M | $679.77M | 2778.37% |
| 2024-03-31 | $4.24B | $124.80M | (m) | $501.74M | $687.44M | 3399.19% |
| 2023-12-31 | $4.27B | $123.24M | (m) | $512.69M | $643.34M | 3467.88% |
| 2023-09-30 | $-1.17B | $103.15M | (m) | $514.51M | $614.32M | -1129.50% |
| 2023-06-30 | $-1.17B | $78.58M | (m) | $514.52M | $607.62M | -1488.10% |
| 2023-03-31 | $-1.18B | $61.28M | (m) | $525.22M | $600.51M | -1917.95% |
| 2022-12-31 | $-1.21B | $43.13M | (m) | $528.43M | (m) | -2800.93% |
| 2022-09-30 | $-1.08B | $50.42M | (m) | $540.25M | (m) | -2134.05% |
| 2022-06-30 | $-1.48B | $51.87M | (m) | $540.35M | (m) | -2852.45% |
| 2022-03-31 | $-1.35B | $55.29M | (m) | $483.04M | (m) | -2444.82% |
| 2021-12-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $-1.07B | $23.80M | (m) | $236.63M | (m) | -4500.52% |
| 2020-12-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |